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ABSTRACT: 
Background: Pharmacokinetic evaluation is one of the key processes in drug discovery and development. 
However, current absorption, distribution, metabolism, excretion prediction models still have limited accuracy. 
Aim: This study aims to construct an integrated transfer learning and multitask learning approach for developing 
quantitative structure-activity relationship models to predict four human pharmacokinetic parameters. 
Methods: A pharmacokinetic dataset included 1104 U.S. FDA approved small molecule drugs. The dataset 
included four human pharmacokinetic parameter subsets (oral bioavailability, plasma protein binding rate, 
apparent volume of distribution at steady-state and elimination half-life). The pre-trained model was trained on 
over 30 million bioactivity data. An integrated transfer learning and multitask learning approach was established 
to enhance the model generalization.  
Results: The pharmacokinetic dataset was split into three parts (60:20:20) for training, validation and test by 
the improved Maximum Dissimilarity algorithm with the representative initial set selection algorithm and the 
weighted distance function. The multitask learning techniques enhanced the model predictive ability. The 
integrated transfer learning and multitask learning model demonstrated the best accuracies, because deep neural 
networks have the general feature extraction ability, transfer learning and multitask learning improved the model 
generalization. 
Conclusions: The integrated transfer learning and multitask learning approach with the improved dataset 
splitting algorithm was firstly introduced to predict the pharmacokinetic parameters. This method can be further 
employed in drug discovery and development. 
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INTRODUCTION 
Early pharmacokinetic parameter prediction is one of the key steps in pharmacokinetic evaluation.1, 2 In 
the 1990s, poor ADMET (absorption, distribution, metabolism, excretion and toxicity) properties were the major 
causes responsible for the attrition of drug candidates in clinical trials.3 In recent 20 years, advances in 
preclinical virtual screening methods have been made to predict the pharmacokinetic properties prior to the 
experiments.4, 5 These methods included physiologically based pharmacokinetic prediction tools and QSAR 
(quantitative structure-activity relationship) approaches. In practice, oral bioavailability (BA), plasma protein 
binding rate (PPBR), apparent volume of distribution at steady-state (VDss) and elimination half-life (HL) were 
four important and commonly measured human pharmacokinetic parameters. They respectively reflected the 
fraction reaching systemic circulation of the dose administered, the fraction binding to plasma proteins of the 
drug in the blood, the in vivo distribution of the drug and the time for eliminating half of the initial drug 
concentration. Currently, the measurements of the four pharmacokinetic parameters still highly rely on the labor-
intensive and costly in vivo and in vitro experiments, which is a heavy burden for the pharmaceutical industry. 
There has been an increasing interest in the in silico QSAR approaches to optimize and replace the experiments 
of BA, PPBR, VDss and HL.6-8 
In recent 20 years, there have been several attempts in QSAR models for the pharmacokinetic parameter 
prediction. Besides rule-of-thumb which contained simple-rule based classification approaches (e.g. the 
Lipinski’s rule-of-five)9 and some empirical equations, machine learning techniques were widely adopted in 
ADME evaluation.	10-19 Machine learning algorithms were used to develop mathematical models by using the 
existing experimental data. Table 1 summarized published studies which applied a various of machine learning 
approaches to BA, PPBR, VDss and HL prediction in recent 20 years. Partial least squares regression (PLSR) 
and support vector machine (SVM) were two popular linear and nonlinear machine learning algorithms in 
pharmacokinetic parameter prediction. For example, in the year 2011, Hou and co-workers developed the 
multiple linear regression (MLR) and genetic function approximation (GFA) models to predict the BA in 
humans. The models were trained on the dataset that included around one thousand drug and drug-like 
compounds. GFA was the methods that combined the genetic algorithm and the multivariate adaptive regression 
splines algorithm.20 In the year 2008, Ma et al. adopted SVM methods with the genetic algorithm and the 
conjugate gradient methods to identify the PPBR as two categories of positive (≥75%) or negative.21 In the year 
2016, Lombardo and co-workers used PLSR and random forest (RF) algorithms to construct the models for 
VDss prediction.22 For HL prediction, in the year 2012, Heidi Kidron and co-workers developed the MLR 
models on a dataset of 47 compounds.23 The conventional machine learning methods required considerable and 
reliable expertise to design the features. But the expertise in molecular structure and pharmacokinetics tend to 
be insufficient and subjective. On the other hand, lots of molecular features and complex ADME mechanism 
also need automatic feature extractors. Therefore, there is still room for improvement in QSAR approaches for 
pharmacokinetic parameter prediction. 
Table 1 Recent progresses in BA, VDss, PPBR and HL prediction 
Objective Data Machine learning method Reference 
PPBR 239 chemicals Partial least squares 24 
PPBR,  
VDss 
320 chemicals 
328 chemicals 
Multiple linear regression 25 
PPBR 115 Beta-lactams Multiple linear regression 26 
PPBR 1008 chemicals 
Multiple linear regression 
Artificial neural networks (ANN) 
k-nearest neighbors 
Support vector machine 
27 
PPBR 853 chemicals Support vector machine 21 
PPBR 
 
1242 chemicals 
k-nearest Neighbors 
Random forest 
Support vector machine 
28 
PPBR 1830 chemicals 
Random forest 
Support vector machine 
Cubist 
29 
Gaussian process 
Boosting 
PPBR 
1837 drugs and 
chemicals 
Random Forest 
Boost Tree 
Multiple Linear Regression 
k-nearest-neighbor 
Support vector regression 
Multi-layer Neural Network 
30  
VDss 
 
584 chemicals Linear squared error model 31 
VDss 121 drugs 
Multiple linear regression 
Artificial neural network 
Support vector machines 
32 
VDss 604 chemicals Decision tree-based regression 33 
VDss 384 drugs Mixture discriminant analysis-random forest model 34 
VDss 
698 drugs and 
chemicals 
Partial least-squares 
Random forest 
35 
VDss 1096 chemicals 
Partial Least Squares 
Random Forest 
22 
Vitreal HL 68 chemicals Multiple linear regression 36 
Vitreal HL 47 chemicals Multiple linear regression 23 
HL 1105 chemicals 
gradient boosting machine 
support vector regressions 
local lazy regression and so on 
37 
BA 591 chemicals Stepwise regression 38 
BA 232 drugs Adaptive least squares 39 
BA 167 drugs Artificial neural networks 40 
BA 302 drugs Partial least squares 41 
BA 768 chemicals Rule-based approaches 42 
BA 772 chemicals Multiple linear regression 43 
BA 766 chemicals Support vector machine 21 
BA 1014 chemicals 
Multiple linear regression 
Genetic function approximation 
20 
BA 
805 drugs and 
chemicals 
Multiple linear regression 
Partial least squares regression 
Support vector machine 
44 
 
Recently, deep learning, which is usually accepted as deep neural networks (DNN), has been widely used 
to make advances in many fields of academia and industry.45-48 The key aspect of deep learning is the general-
purpose feature extraction procedure, which can automatically transform raw data into higher-level features. 
The intricate structure and minute variations of the high-dimensional data can be discovered by deep learning 
without human expertise.49, 50 In recent years, many successes have also been made by deep learning in drug 
discovery and formulation development.51, 52 For examples, in the year 2013, compared with other machine 
learning methods, deep learning yielded good performance in aqueous solubility prediction based on the 
undirected graphs.53 In the year 2015, it was found that deep learning could reach or exceed the performance of 
the RF algorithms on a series of Merck’s drug discovery datasets.54  
The most difficulty in ADME evaluation is the lack of sufficient and high quality data. By utilizing the 
massive bioactivity data to find out the common low level features, the accuracies of ADME models can be 
enhanced by transfer learning. Transfer learning aims to transfer known knowledge to the target domain to 
improve the learning.55 Leveraging the common features learned from the similar source domain, transfer 
learning has been demonstrated to be able to develop the models without learning from scratch.56-58 Recently, 
in the medical field, transfer learning has made great progress in identifying optical coherence tomography 
images to aid medical decision making.59 Activity-related chemical characteristics of molecules can be 
discovered by deep learning on the massive molecular structure and bioactivity measurements on the basis of 
the assumption that similar molecules have similar properties.60 The chemical characteristics can be transferred 
to the pharmacokinetic models by transfer learning. Furthermore, by uncovering the low level common features 
among multiple tasks simultaneously, it was found that multitask learning was able to improve the model 
generalization.61 Multitask learning has been reported to be applied to drug discovery.62-65 
Nowadays, there are over 30 million bioactivity data which include hundreds of thousands of molecules. 
These bioactivity data include the molecular structure and the bioactivity measurements. Bioactivity 
measurements described the activities of compounds against the biological targets. Rather than developing the 
ADME model from a model with initialization weights, the model could be obtained through retraining the 
weights which have been pre-optimized on a large bioactivity database for the pharmacokinetic parameter 
prediction (Figure 1).  
In this paper, transfer learning and multitask learning methods were applied to the pharmacokinetic 
parameter prediction. In detail, a pharmacokinetic dataset comprising four critical human pharmacokinetic 
parameters was built and a large bioactivity dataset containing over 30 million entries was introduced. The 
specific evaluation criterion suitable for pharmacokinetics and the automatic dataset splitting algorithm were 
developed. The deep neural networks were trained by using the integrated transfer learning and multitask 
learning approach. Compared with other machine learning methods, higher accuracies and stronger 
generalization of the present models were shown by the results. 
 
METHODS 
1. Pharmaceutical Data 
1.1. Pharmacokinetic Dataset 
The pharmacokinetic dataset contained 1104 approved drugs, which was a union of the four subsets. The 
subsets included a BA subset of 410 molecules, a PPBR subset of 769 molecules, a VDss subset of 412 
molecules and a HL subset of 969 molecules. The approved drug list was obtained from U.S. Food and Drug 
Administration. The pharmacokinetic information of the drugs was retrieved from Drugbank database.66 The 
information was manually normalized to the quantitative data. In this study, the data determined in healthy 
adults were adopted rather than the elder, children and patients. The data of instant release dosage forms were 
reserved rather than sustained release dosage forms.  
1.2. Bioactivity Dataset for Developing the Pre-trained Model 
The pre-trained model for transfer learning was trained on the large bioactivity dataset. This large 
bioactivity dataset contained more than 30.9 million entries of qualitative data and was obtained from 
Deepchem.67 This dataset included 486904 molecules and 157 targets. Three subsets of PCBA, MUV and Tox21 
in this dataset were collected from PubChem database and the 2014 Tox21 Data Challenge by DeepChem.68  
2. Representation of molecular structure 
The molecules used in this study were characterized by Extended-Connectivity Fingerprints (ECFPs).69 
ECFPs were designed for developing QSAR models. ECFPs have been widely used in the fields of 
cheminformatics and bioinformatics. In this study, the ECFPs were generated by using the open source package 
RDKit.70 The Canonical SMILES of the molecules were used as the input of RDKit, the length and radius of 
the ECFPs were set to 1024 and 2. The Canonical SMILES were obtained from PubChem database.68 
Because ECFPs are binary data which are not suitable for the molecular similarity calculating for dataset 
splitting, the eight molecular descriptors commonly used were adopted to calculate the similarity for dataset 
splitting. The eight molecular descriptors of the approved drugs were obtained from PubChem database.68 The 
descriptors included Molecular Weight, Topological Polar Surface Area, Rotatable Bond Count, Hydrogen Bond 
Donor Count, Hydrogen Bond Acceptor Count, Heavy Atom Count, Complexity and Covalently-Bonded Unit 
Count. 
3. Three-dataset Splitting Strategy 
The three-dataset splitting strategy was widely accepted in the field of machine learning. In this study, the 
pharmacokinetic dataset was split into three subsets (training/validation/test subsets). The training subset was 
for training models. The validation subset was for tuning the hyper-parameters to find the best model. The test 
subset was for testing the model performances on an external dataset. The training, validation and test subsets 
contained 664, 220 and 220 drugs, respectively. 
4. Metric Criteria 
4.1. Pharmacokinetic Task 
In machine learning, correlation coefficient and determinant coefficient were two common metric criteria 
used to evaluate the linear relationship between the real values and the predicted values. However, both of them 
can’t well reflect the real performances of the QSAR models in ADME evaluation. The absolute error (AE) was 
introduced to evaluate the accuracies of the machine learning models. The AE was defined as the difference 
between a real value and a predicted value. In pharmacokinetic parameter prediction, if the AE is no more than 
10%, it can be thought of a successful prediction. Therefore, the accuracy is the percentage of the successful 
predictions in all predictions: 
 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 = 𝑁𝑢𝑚𝑏𝑒𝑟( 𝐴𝐸 ≤ 0.1)𝐴𝑙𝑙𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛𝑠  
 
In addition, the MAE (mean absolute error) was also used as metrics and defined as follow: 
 
𝑀𝐴𝐸 = 𝑦<=>?@ − 𝑦<BCD?BE<FG 	𝑛  
 
Where, n is the number of samples, 𝑦=>?@ are the prediction values, 𝑦BCD?B are the experimental values. 
4.2. Bioactivity Task of the Pre-trained Model 
In machine learning, receiver operating characteristic (ROC) curve was commonly used to evaluate 
performances for classification problems. Though the bioactivity dataset contains 30.9 million entries, only 
0.433 million entries (about 1.4% of the total entries) are active and the residual entries are negative. Thus, a 
recall value was more suitable than ROC curve in this case. The recall was defined as: 
 
𝑅𝑒𝑐𝑎𝑙𝑙 = 𝑇𝑃𝑇𝑃 + 𝐹𝑁 
 
Where, TP is true positive, FN is false negative. 
5. Hyper-parameters of Conventional Machine Learning Algorithms 
    Regression models were constructed on the basis of the five machine learning algorithms containing PLSR, 
SVM, ANN, RF and k-nearest neighbors (k-NN). These QSAR models were built using the sci-kit learn package 
in Python programming language.71 For BA, PPBR, VDss and HL, in PLSR, the number of components was 
chosen as 5, 6, 2 and 5. In ANNs, the networks containing 1 hidden layer with 200, 600, 500 and 400 hidden 
nodes were adopted. In RF, the maximum depths of the tree of 10, 15, 10, 5 were used. In k-NN, 5, 2, 20, 20 
were set as the numbers of neighbors. 
6. An Integrated Transfer Learning and Multitask Learning Approach 
6.1. Multitask Learning Model 
The multitask learning feed-forward  neural network was developed on the pharmacokinetic dataset. The 
model was trained on the basis of the DeepLearning4j framework in Java programming language. This network 
contained 10 dense layers. The hidden nodes in the 10 layers were set from 1000 to 100 with a drop of 100 
nodes per layer. The epoch was set to 100. The learning rate was set to 0.1. The β1, β2 and λ were set to 0.5, 
0.999 and 0.01, respectively. The tanh was chosen as the activation function except the last layer with the 
sigmoid activation function. 
6.2. Pre-trained Model 
The pre-trained model was developed on the bioactivity dataset. This neural network was trained on the 
DeepLearning4j framework in Java programming language. 11 dense layers including 10 feature extraction 
layers and 1 task layer were adopted in this network. The hidden nodes in the feature extraction layers were set 
from 1000 to 100 with a drop of 100 nodes per layer. The task layer contained 1000 hidden nodes. The epoch 
was set to 5. The learning rate was set to 0.01. The β1, β2 and λ were set to 0.5, 0.999 and 0.01, respectively. 
The tanh was chosen as the activation function except the last layer with the sigmoid activation function. 
6.3. DeepPharm Models 
Three feed-forward neural networks (DeepPharm-BA, DeepPharm-PPBR and DeepPharm-VDss&HL 
models) were developed. The models were trained using the integrated transfer learning and multitask learning 
approach (DeepPharm) on the DeepLearning4j framework in Java programming language. The framework of 
this approach was illustrated in Figure 1. The three deep neural networks contained 11 dense layers of 10 feature 
extraction layers and 1 task layer. The hidden nodes in the feature extraction layers were set from 1000 to 100 
hidden nodes with a drop of 100 nodes per layer. The internal weights of the feature extraction layers of the 
three networks were transferred from the pre-trained model and retrained on the pharmacokinetic dataset. 96 
epoch and a task layer of 1000 hidden nodes were used to develop the DeepPharm-BA model. 52 epoch and a 
task layer of 1000 hidden nodes were used to develop the DeepPharm-PPBR model. 96 epoch and a task layer 
of 100 hidden nodes were used to develop the DeepPharm-VDss&HL model. The learning rate was set to 0.03, 
the β1, β2 and λ were set to 0.5, 0.999 and 0.01. The tanh was chosen as the activation function except the last 
layers with the sigmoid activation function. 
	 Figure 1 The framework of the integrated transfer learning and multitask learning approach (DeepPharm) 
 
RESULTS 
1. Dataset Splitting Algorithms 
The data ranges and distributions of the four pharmacokinetic parameters were different. The ranges of BA 
and PPBR were from 0% to 100%. The VDss and HL were no more than 2000L and 168h. The distributions of 
VDss and HL data were extremely imbalance. Over 75% VDss data concentrated on the range of 0-100L. Over 
60% HL data were less than 10 hours. Therefore, an investigation of the automatic dataset splitting algorithms 
for the pharmacokinetic dataset splitting was required. 
Firstly, the random dataset splitting was carried out. An analysis of the performance of dataset splitting 
algorithms was implemented. The split training, validation and test subsets were equally divided into 10 groups 
according to the subset ranges, respectively. Subset error (SE) was introduced to evaluate the representativeness 
of the split subsets. SE was defined as: 
 
SE = (𝑀𝑎𝑥𝐹𝑟𝑒𝑞< − 𝑀𝑖𝑛𝐹𝑟𝑒𝑞<)E<FG 𝑛  
 
where, 𝑀𝑎𝑥𝐹𝑟𝑒𝑞 is the maximum frequency of the data in each group among the training, validation and 
test subsets, 𝑀𝑖𝑛𝐹𝑟𝑒𝑞 is the minimum frequency of the data in each group among the training, validation and 
test subsets. 𝑛 is the number of the groups and set to 10. The results of the large SE values indicated that random 
splitting methods couldn’t select the representative subsets from the pharmacokinetic dataset. 
Recently, an automatic splitting algorithm (the MD-FIS algorithm) selecting the representative subsets 
from the formulation dataset was published by us.51, 52 But the pharmacokinetic data were different from the 
formulation data, the pharmacokinetic data were imbalanced in the distributions of the eight molecular 
descriptors and the pharmacokinetic parameters. Therefore, a new MD-FIS algorithm (MD-FIS-WD) with the 
Weighted Distance function was developed in R programming language for improving the splitting performance. 
The weighted distance function was defined as: 
 Distance = wGd + 𝑤\p 
 
Where, wG  and 𝑤\  can control the proportion of the molecular descriptors and the pharmacokinetic 
parameters, d is the molecular descriptor and p is the pharmacokinetic parameter. Finally, wG and 𝑤\were set 
to 0.7 and 0.3 to get the best splitting performance. The SE values of BA, PPBR, VDss and HL were 4.21, 3.18, 
4.32 and 3.87, respectively. The SE values yielded by MD-FIS-WD were smaller than those got by random 
splitting methods and the MD-FIS algorithm considering only the molecular descriptors. The training, validation 
and test subsets split by the MD-FIS-WD algorithm were used to develop machine learning models. 
 2. Conventional Machine Learning Methods 
Five machine learning algorithms including PLSR, SVM, ANNs, RF and k-NN were introduced to develop 
QSAR models for pharmacokinetic evaluation. Table 2 showed the accuracies of the five machine learning 
models on training, validation and test sets. On the test set, for BA, the accuracies of the five machine learning 
models were around 20% with the lowest accuracy of 15.07% of ANN and the highest accuracy of 23.29% of 
SVM. The RF model got an accuracy of 21.92% inferior to the SVM model. For PPBR, the accuracies of the 
five models were around 30%. The ANN model got the best results of 33.56%. The SVM, RF and k-NN models 
got the same accuracies of 31.54% closed to the ANN model. For VDss, the five model accuracies were from 
40.66% to 60.44%. The k-NN model got the highest accuracy of 60.44% among them. The SVM model got the 
second highest accuracy of 52.75%. For HL, the lowest accuracy was 52.00% of the ANN model and the highest 
accuracy was 66.29% of the RF model. The k-NN model got an accuracy of 65.71% closed to the RF model. 
  
Table 2 Accuracy and MAE values of BA, PPBR, VDss and HL on training, validation and test sets 
Characteristic Machine Learning 
Training set Validation set Test set 
Accuracy MAE Accuracy MAE Accuracy MAE 
BA 
PLSR 95.45 0.0341 35.04 0.2476 20.55 0.3144 
SVM 90.45 0.0435 29.91 0.2707 23.29 0.3418 
ANN 96.82 0.0217 30.77 0.2736 15.07 0.3749 
RF 43.64 0.1363 27.35 0.2459 21.92 0.2756 
k-NN 29.09 0.1990 23.93 0.2543 19.18 0.3266 
Multi-task 92.27 0.0318 37.61 0.2518 25.00 0.3019 
DeepPharm 86.36 0.0503 32.48 0.2570 27.78 0.3122 
PPBR 
PLSR 92.98 0.0416 31.10 0.2337 30.87 0.2759 
SVM 98.90 0.0213 29.27 0.2633 31.54 0.2883 
ANN 99.56 0.0130 34.15 0.2509 33.56 0.2789 
RF 68.64 0.0882 27.44 0.2325 31.54 0.2368 
k-NN 69.08 0.0951 43.90 0.2226 31.54 0.2604 
Multi-task 80.09 0.0703 46.58 0.1897 42.86 0.2196 
DeepPharm 41.37 0.2049 41.61 0.2528 44.22 0.2481 
VDss 
PLSR 97.36 0.0327 68.09 0.1187 49.45 0.1759 
SVM 99.56 0.0241 67.02 0.1213 52.75 0.1766 
ANN 98.68 0.0210 53.19 0.1501 40.66 0.2020 
RF 83.26 0.0587 52.13 0.1387 48.35 0.2092 
k-NN 81.94 0.0791 77.66 0.1124 60.44 0.1917 
Multi-task 98.24 0.0119 72.34 0.1075 61.11 0.1732 
DeepPharm 96.04 0.0270 78.72 0.0982 63.33 0.1735 
HL 
PLSR 98.23 0.0269 68.97 0.1114 56.00 0.1464 
SVM 95.81 0.0363 68.39 0.1085 56.00 0.1476 
ANN 96.77 0.0215 51.72 0.1338 52.00 0.1514 
RF 88.06 0.0486 78.16 0.0925 66.29 0.1269 
k-NN 87.74 0.0508 81.61 0.0879 65.71 0.1338 
Multi-task 89.19 0.0520 77.59 0.0926 68.39 0.1259 
DeepPharm 94.19 0.0327 78.74 0.0873 66.67 0.1216 
 
 
 
 
3. The Integrated Transfer Learning and Multitask Learning Approach 
3.1. Multitask Learning Model 
Multitask learning techniques were implemented to develop a deep neural network. Conventional multitask 
learning methods cannot solve the problem that the training set is imbalanced with missing label values. A 
dynamic weighted cost function was introduced to give different weights for different pharmacokinetic 
parameters. 
 cost = 𝑤G𝑐G + 𝑤\𝑐\ + 𝑤_𝑐_ + 𝑤`𝑐` 
 
Where, 𝑤G, 𝑤\, 𝑤_ and 𝑤` can control the costs of BA, PPBR, VDss and HL, respectively. Finally, the 
weights were set to 𝑤G:	𝑤\:	𝑤_:	𝑤` = 3: 1: 9: 1. The results of the multitask learning deep neural network were 
shown in table 2. For all pharmacokinetic parameters, on the test set, the accuracies of the multitask learning 
model were higher than the five conventional machine learning algorithms. 
3.2. Pre-trained Model 
The integrated transfer learning and multitask learning approach was implemented for better model 
generalization and predictive ability. A pre-trained model was developed on the large bioactivity dataset. The 
bioactivity dataset was randomly divided into two parts of the training set and the validation set. The results 
showed the recall values were 49.51% on the training set, and 32.02% on the validation set. Furthermore, a 
weighted cost function was introduced to enhance the proportion of the costs of the active data. 
 
wcost = 𝑤G 𝑝𝑣 − 𝑙𝑣 \2 	𝑖𝑓	𝑙𝑎𝑏𝑒𝑙 = 1𝑤\ 𝑝𝑣 − 𝑙𝑣 \2 	𝑖𝑓	𝑙𝑎𝑏𝑒𝑙 = 0 
 
Where, 𝑤G and 𝑤\ can control the costs of active data (𝑙𝑎𝑏𝑒𝑙 = 1) and negative data (𝑙𝑎𝑏𝑒𝑙 = 0), 𝑝𝑣 is the 
predictive value, 𝑙𝑣 is the label value. Finally, 𝑤G:	𝑤\ = 100:	1 was used, which resulted in the recall values of 
87.42% on the training set, 85.05% on the test set.  
3.3. DeepPharm Models 
The three deep neural networks (DeepPharm-BA, DeepPharm-PPBR and DeepPharm-VDss&HL) were 
developed using the integrated transfer learning and multitask learning approach. Usually, a consensus model 
can take the advantages of various models 20, 72. The consensus model (DeepPharm model) took the optimal 
prediction for each of the four pharmacokinetic parameters from the three networks. The accuracies of the 
DeepPharm model were shown in Table 2. On the test set, the DeepPharm model got the highest accuracies of 
27.78%, 44.22% and 63.33% in BA, PPBR and VDss prediction. For HL, on the test set, the DeepPharm model 
got the closed result of 66.67% to the multitask model result of 68.39% and was superior to other conventional 
machine learning methods. Table 3 showed the DeepPharm model performance on the basis of the metric criteria 
using different benchmarks of 10%, 20% and 30%. When the benchmark was set to 20%, the accuracies of the 
DeepPharm model were more than 75% in VDss and HL prediction. 
 
Table 3 Accuracies across different metric criteria using the benchmarks of 10%, 20% and 30% of the 
DeepPharm model for BA, PPBR, VDss and HL on the test subsets 
Characteristic % ≤ 10% error % ≤ 20% error % ≤ 30% error 
BA 27.78 41.67 51.39 
PPBR 44.22 59.86 67.35 
VDss 63.33 75.56 78.89 
HL 66.67 81.03 90.23 
 
DISCUSSION 
The lack of sufficient and high quality data is one factor of the difficulties in ADME evaluation. The high 
cost of clinical trials results in the lack of reliable pharmacokinetic data. This problem has been mentioned in 
many previous studies.22, 44, 54, 73, 74 Generally, the validation and the test sets should have the same probability 
distribution with the training set. Random splitting may lead to an imbalanced dataset splitting on a small dataset. 
Many studies used the k-fold or leave-one-out (LOO) cross-validation methods to evaluate the model 
performance, while the k-fold and LOO cross-validation methods may get overoptimistic results.75 In this study, 
the MD-FIS-WD automatic dataset splitting algorithm was developed to handle the pharmacokinetic dataset 
splitting problem. Considering both molecular structure and pharmacokinetic parameter distributions, this 
algorithm works well according to the data splitting results. Moreover, molecular representation of compounds 
is also an important factor to predict the ADME parameters. In our manuscript, the ECFP_4 molecular 
fingerprint were used as the input of both bioactivity dataset and PK predictions. 
The third factor is the algorithm. As shown in Table 1, in recent 20 years, several QSAR models have been 
trained for the pharmacokinetic parameter prediction. They performed better than the rule-of-thumb, such as 
simple rule-based classification methods and empirical equations. These models were learned from in vitro and 
in vivo experimental data by a serious of machine learning approaches. The physicochemical properties, 
molecular descriptors and molecular fingerprints were used for the representation of molecular structure.76 For 
example, in the year 2012, Xu et al. compared multiple linear regression to partial least squares regression and 
support vector machine for BA prediction. The models were generated using molecular descriptors.44 In the year 
2017, Cao and co-workers presented models developed by RF, SVM, Cubist, Gaussian process, and Boosting 
for PPBR prediction. The molecular descriptors used in the work were selected by non-dominated sorting 
genetic algorithms and partial least squares regression.29 In the year 2015, Alex et al. applied decision tree 
methods to VDss prediction based on molecular descriptors and tissue: plasma partition coefficients.33 In the 
year 2016, Lu et al. developed QSAR models based on a dataset of 1105 organic chemicals for HL prediction.37 
However, conventional machine learning algorithms highly relied on feature engineering. Feature engineering 
was time-consuming and challenging due to human experts’ subjective and vague experiences, which resulted 
in bad model performance. In our study, deep learning can automatically extract the critical features or molecular 
descriptors from the raw data without the need of feature engineering. The key aspect of deep learning is the 
general-purpose feature extraction procedure, which can automatically transform raw data into higher-level 
features. 
Moreover, four independent variables in PK-related property (BA, PPBR, VDss and HL) were predicted 
by integrated transfer learning and multi-tasks approach. Applying multitask learning, the deep neural network 
performed better than other single-task machine learning methods. Because multitask learning could utilize the 
data of multiple tasks to discover the correlations and distinguish the differences among multiple tasks. 
Leveraging the bioactivity data, transfer learning further enhanced the model generalization ability. Transfer 
learning achieved good prediction ability by reusing the features of the pre-trained model as the initial model 
weights. Furthermore, transfer learning techniques could save computing resources and time for model 
optimization as well. The good model generalization was showed by the external unseen test dataset. With the 
increase of reliable pharmacokinetic data, future models may benefit more by using this approach.  
In this research, we found that the nonlinear machine learning models performed better than the linear 
PLSR models. Obviously, the relationships between the molecular structure and the pharmacokinetic parameters 
are non-linear. In many cases, the random forest models are superior to other conventional machine learning 
algorithms. Random forest has more complex non-linear model structure than other methods by aggregating 
decision trees, which could construct a more complex function mapping. Random forest is more likely to depict 
the nonlinear relationship between the molecular structure and the pharmacokinetic parameters. In addition, 
generally, deep neural networks directly optimized on a large dataset would get higher accuracy than transfer 
learning because the models could be directly trained for the specific task. However, the main difficulty in 
ADME evaluation was the small dataset with imbalanced input space. Compared to the models developed from 
the weights using random initialization, transfer learning could obtain more accurate models on small training 
datasets. Furthermore, the feature extraction layers of a pre-trained model are very important in transfer learning. 
A pre-trained model trained on large and high quality relevant dataset would enhance the performance of the 
target model. 
As described above, we demonstrated the integrated transfer learning and multitask learning approach for 
BA, PPBR, VDss and HL prediction, which provided a reference for the ADME evaluation and may accelerate 
the drug discovery and development. BA, as a complex pharmacokinetic parameter determining the 
administered dose, depends highly on several absorption, transport and metabolism mechanisms in 
gastrointestinal absorption and excretion process, in gut wall first-pass process and in hepatic first-pass process. 
PPBR is an important pharmacokinetic parameter. Generally, it is assumed that only free drugs could pass 
through the vascular wall. The combined drug in the blood is a reservoir, which would cause drug overdose and 
toxicity. PPBR has an impact on the VDss. VDss is a theoretical parameter which reflects in vivo distribution 
of a drug. A low VDss value generally indicates that the drug concentrate in the vascular and a high VDss value 
indicates extensive drug distribution in the body. HL is influenced by clearance and VDss. HL describes the 
time for decreasing half of the initial plasma drug concentration. HL is an important pharmacokinetic parameter. 
HL determines the administered frequency of a drug.	 Considering the importance of preclinical ADME 
evaluation, more applications of this approach may be carried out for the prediction of other pharmacokinetic 
parameters. Besides pharmacokinetic parameter prediction, more attempts of the integrated transfer learning 
and multitask learning approach may exceed the field of pharmacokinetics in the future. 
 
CONCLUSIONS 
In this paper, an integrated transfer learning and multitask learning approach with the MD-FIS-WD dataset 
splitting algorithm was successfully established to develop QSAR models to predict four critical human 
pharmacokinetic parameters on the approved drug dataset. The final DeepPharm model showed the best 
performance and generalization ability than other conventional machine learning approaches  because deep 
neural networks have the general feature extraction ability and transfer learning improves the model 
generalization.	Our integrated transfer learning and multitask learning approach may reveal a broad prospect of 
the application in future pharmaceutical researches. 
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